Philips announces expansion of ultrasound portfolio

Philips has expanded its ultrasound portfolio with new advanced hemodynamic assessment and measurement capabilities, which recently received 510(k) clearance from the Food and Drug Administration (FDA) to its Lumify handheld point-of-care ultrasound solution. 

With this latest addition of Pulse Wave Doppler, Philips handheld ultrasound enables clinicians to quantify blood flow in point-of-care diagnostic applications – including cardiology, vascular, abdominal, urology, obstetrics and gynaecology. New enhancements to Lumify also include obstetric measurements to help in early assessment of gestational age and the identification of high-risk pregnancies.

Point-of-care hemodynamic

Pulse Wave Doppler ultrasound allows clinicians to diagnose in critical situations beyond 2D and colour imaging to assess hemodynamic patterns to differentiate between arterial and venous blood flow and quantify hemodynamic function. The resulting hemodynamic measurements can significantly enhance diagnostic confidence and timely clinical decision-making in virtually any care setting, including cardiology and emergency medicine. With these latest features Lumify brings together imaging tools leveraging Philips’ expertise across ultrasound platforms. The Lumify system also provides clinicians with analysis software and reporting tools, and access to tele-ultrasound capabilities (Lumify with Reacts) for live communication support to connect clinicians around the globe for real-time collaboration. 

Matthijs Groot Wassink, general manager of point of care ultrasound at Philips, said: “By applying Philips’ leading cardiovascular, imaging and patient monitoring expertise to Lumify, we are committed to deliver a dedicated point-of-care innovative portfolio, enabling clinicians to quickly assess hemodynamics – including cardiovascular function, organ perfusion and assessing health of a foetus – in a daily routine, to identify abnormalities and intervene quickly. With the addition of Pulse Wave Doppler and enhanced obstetrics measurements, we have significantly increased the number of markers on which diagnoses can be made, to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real-time.” 

Dr. Robert Jones, professor of Emergency Medicine at the MetroHealth System, Cleveland, Ohio added: “Having Colour Flow Doppler (CFD) and Pulse Wave Doppler on a handheld device is game changing, allowing clinicians to take point-of-care ultrasound examinations to the next level.”